UNISOUND AI TECHNOLOGY CO., LTD.
雲知聲智能科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9678)

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Sole Overall Coordinator and Sole Placing Agent

The Board is pleased to announce that all the conditions under the Placing Agreement have been satisfied and that the completion of the Placing took place on January 22, 2026.

A total of 780,000 new H Shares, representing approximately 1.84% of the H Shares in issue and approximately 1.08% of the total number of Shares in issue as enlarged by the allotment and issuance of the Placing Shares immediately upon completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of HK$252.00 per H Share upon the terms and subject to the conditions set out in the Placing Agreement.

Reference is made to the announcement of Unisound AI Technology Co., Ltd. (the "**Company**") dated January 16, 2026 (the "**Announcement**") in relation to the placing of 780,000 new H Shares under the General Mandate. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

REASONS FOR THE PLACING

Since the Company's listing on June 30, 2025, the AI sector has experienced explosive growth, with continuous iteration of technological innovation and vigorous development of business models. In this context, in order to further consolidate and enhance the Company's leading position in the industry, the Company will continue to strengthen the investment in the following areas to ensure that the Company's core competitiveness remains robust and sustainable.

(a) R&D Capabilities

In order to meet the needs of market competition, the Company will vigorously enhance its R&D capabilities, continuously strengthen investment in Atlas AI infrastructure and UniBrain, and continuously upgrade the professional capabilities of its large models. In order to adapt to the latest competitive landscape of the industry, the Company urgently needs to consolidate its full-stack AI technological advantages and accelerate the industrial application of large models and AI agent technologies through precise capital allocation and targeted technical development. The Company will comprehensively upgrade the Atlas AI infrastructure to V2.0 across three areas, including the training framework, the inference framework, and the AI agent development and management platform. The Company recently released the "UniGPT Medical Large Model 5.0" version, an professional large model in the medical field, achieving significant progress in multimodal capabilities, AI agents, and autonomous reasoning. The Company will continue to advance the iterative upgrades and performance optimisation of the "UniGPT Medical Large Model 5.0".

The resulting new R&D requirements represent new directions for funding, which differ from the specific intended use of proceeds from the Global Offering. The proceeds raised by the Company from the Global Offering will continue to be used in accordance with the expected purposes described in the Prospectus. Based on the Company's assessment, in order to further enhance R&D capabilities, the Company needs to upgrade and expand existing computing power, optimise the supercomputing platform scheduling system, and improve AI technology development capabilities, among other initiatives. The expenses involved in hardware, software and service procurement, IDC data center service leasing, and computing power leasing are estimated to be approximately HK$95.5 million.

(b) Emerging Business Opportunities

Leveraging its leading technological capabilities, the Company will continue to establish a strong presence in key business areas and deepen engagement with lighthouse clients, with business expansion progressing faster than expected. In the smart healthcare sector, the Company will continuously deepen cooperation with numerous Grade A tertiary hospitals including Friendship Hospital, and replicate its capabilities into related fields, successfully establishing in-depth cooperation with insurance companies as well as local medical insurance bureaus and health commissions. In the smart living sector, the Company's chip-related and other hardware businesses have developed rapidly, while also achieving high-quality implementation of solutions and significant business growth in areas such as transportation, cockpits, and industrial parks. Robust business opportunities have resulted in a substantial acceleration of the Company's plan for the use of net proceeds from the Global Offering and the exercise of the over-allotment option, and have given rise to new funding requirements.

In addition, the Company is making vigorous efforts to pursue new sustainable business models and actively explore innovative project opportunities. Currently, projects involving seven categories are under development or planning. For example, in terms of developing the medical insurance and chronic disease management sub-platform, the Company has won the bid for the "Vertical Large Model Development and Scenario Application" project of Jiangsu Provincial Medical Insurance; in terms of developing the regional characteristic industry service sub-platform, the Company is currently in discussions with the government of Hui'an County, Quanzhou City, Fujian Province regarding the planning and development of the "Stone Carving Industry Modular Space and AI Agent Industrial Base" project; in terms of leveraging large model technology to reconstruct applications such as medical record comprehension, medical record generation, chronic disease management, and medical insurance fund supervision, the Company is advancing the Jiangsu Provincial Hospital of Traditional Chinese Medicine project. These initiatives involve software and hardware procurement, service procurement, R&D and sales personnel investment, and marketing expenses, with an estimated total funding requirement of approximately HK$77.4 million.

(c) Working Capital and General Corporate Purposes

In terms of working capital and general corporate use, the estimated funding requirements for property rentals, renovation costs for newly established offices and showrooms, and other related expenses amount to approximately HK$19.2 million.

Based on the above, the total estimated funding requirement for 2026 is HK$192 million. Accordingly, the Company initiated the Placing to cover the above business needs.

In view of the above, conducting the Placing shortly after the listing aligns with the Company's business development plan and actual operational needs. The use of proceeds from the Placing is clear, detailed, and reasonably estimated, and carries a certain degree of urgency. The amount of funds raised is largely consistent with the estimated funding requirements, and raising fund will support the Company in undertaking targeted technical development, maintaining technological advantages in relevant vertical domains, and capturing emerging business opportunities. The Placing is sufficiently reasonable both in terms of timing arrangement and scale, and represents an important initiative to promote the Company's strategic upgrade, further improve its technological strength and customer experience. For further details of the use of the proceeds from the Placing, please refer to "USE OF THE PROCEEDS FROM THE PLACING" of this announcement.

COMPLETION OF THE PLACING

The Board is pleased to announce that all the conditions under the Placing Agreement have been satisfied and that the completion of the Placing took place on January 22, 2026.

A total of 780,000 new H Shares, representing approximately 1.84% of the H Shares in issue and approximately 1.08% of the total number of Shares in issue as enlarged by the allotment and issuance of the Placing Shares immediately upon completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of HK$252.00 per H Share upon the terms and subject to the conditions set out in the Placing Agreement.

To the best of the knowledge, information and belief of the Directors, having made all reasonable enquiries, the Placees and their respective ultimate beneficial owners, are Independent Third Parties. None of the Placees becomes a substantial shareholder (as defined under the Listing Rules) of the Company immediately after the completion of the Placing.

EQUITY FUND RAISING ACTIVITY IN THE PAST TWELVE MONTHS

On June 30, 2025, the H Shares were listed on the Main Board of the Stock Exchange. After deducting underwriting fees, commissions and other offering expenses, the net proceeds from the Global Offering and the exercise of the Over-allotment Option (as defined in the Prospectus) amounted to approximately HK$236.94 million (the "**Net Proceeds**"), which will be utilized for the purposes as set out in the Prospectus.

The intended and actual usage of the Net Proceeds as of the date of this announcement are set out below:

Intended use of the net proceeds		Net proceeds from the listing available (HK$ million)	Percentage of use of proceeds raised (%)	Actual net amount utilized as of the date of this announcement (HK$ million)	Unutilized net amount as of the date of this announcement (HK$ million)	Expected timeline for fully utilizing the unutilized net amount	Expected timeline as disclosed in the prospectus
Enhance R&D capabilities	Invest in Atlas AI infrastructure	73.00	30.81%	61.85	11.15	On or before September 30, 2026	Within five years of listing
	Upgrade the UniBrain	18.30	7.72%	17.53	0.77	On or before September 30, 2026	
	Talent cultivation and joint R&D	16.75	7.07%	4.07	12.68	On or before September 30, 2026	
Invest in emerging business opportunities and increase the adoption and penetration of products in vertical industries and scenarios	R&D personnel investment	64.45	27.20%	11.06	53.39	On or before September 30, 2026	Within five years of the listing
	Sales personnel investment	36.33	15.33%	1.64	34.69	On or before September 30, 2026	
	Marketing and promotional expenses	10.58	4.47%	0.39	10.19	On or before September 30, 2026	
Working capital and general corporate use	Inventory	17.53	7.40%	5.27	1.91	On or before September 30, 2026	—
	Service fees			6.13			
	Rentals and property management fees			2.12			
	Other working capital expenditures			2.10			
Total		**236.94**	**100.00%**	**112.16**	**124.78**	**—**	**—**

Note: Due to rounding, there may be a difference between the sum of the individual sub-values and the total amount. The expected timeline for fully utilizing unutilized net amount is based on the Company's forecasts, which is subject to the current and future development of the market conditions.

The expected timeline for full utilization of the net proceeds has been accelerated compared to the expected timeline disclosed in the Prospectus, due to continuous R&D investment and robust business opportunities.

Save as disclosed above and the Placing, the Company has not carried out any equity fund raising activities in the past 12 months immediately preceding the date of this announcement.

USE OF PROCEEDS FROM THE PLACING

The gross proceeds and net proceeds (after deducting the commissions and estimated expenses) from the Placing amounted to HK$196.56 million and approximately HK$191.69 million, respectively.

The net proceeds from the Placing are expected to be fully utilized by December 31, 2026, of which: (i) approximately 50% will be used to enhance R&D capabilities; (ii) approximately 40% will be used to invest in emerging business opportunities; and (iii) approximately 10% will be used for working capital and general corporate use. Specifically:

I. Enhance R&D Capabilities

Approximately 50% of the net proceeds from the Placing will be dedicated to the enhancement of R&D capabilities, focusing on three major directions: strengthening AI infrastructure, upgrading core technology platforms, and building a talent ecosystem. Through precise capital allocation and targeted technical development, the Company aims to consolidate its full-stack AI technological advantages and accelerate the industrial application of large models and AI agent technologies. Details of the specific allocation of funds and implementation are as follows:

(a) Strengthen the Atlas AI Infrastructure (representing approximately 24% of the net proceeds from the Placing)

This portion of the proceeds will be used to upgrade the Atlas AI infrastructure to V2.0 across three areas, including the training framework, the inference framework, and the AI agent development and management platform, with the aim of comprehensively improving the software and hardware capabilities of the Atlas AI intelligent computing platform, focusing on breaking through the computing power support bottlenecks for AI agent applications and achieving an architectural upgrade from “computing power supply” to “efficient empowerment of AI agents.”

In terms of training framework, at the software level, the distributed training framework will be iterated and upgraded to support parallel training capabilities for large models with trillions of parameters; at the computing power level, the computing capacity has advanced from the current 500 PFLOPS toward 1,000 PFLOPS, generally shortening the iteration cycle for core foundation models such as the UniGPT large model by more than 40%.

In terms of inference framework, the Company will further deepen the inference infrastructure, and develop adaptive inference engines integrating advanced decoding strategies and model compression algorithms to address the real-time interaction needs of AI agents. This aims to achieve precise control over inference latency while supporting the concurrent scheduling of multiple AI agents, thereby meeting the large-scale application demands in high-frequency scenarios such as medical consultations and smart cockpit interactions.

Furthermore, the Company will upgrade the AI agent development and management platform. In particular, the Company will specifically develop an AI agent application orchestration module to optimize communication protocols and task allocation algorithms for multi-agent collaboration, enabling the rapid assembly and flexible invocation of AI agents across different scenarios. At the same time, the Company will upgrade the platform's data processing capabilities by strengthening toolchains such as intelligent annotation and data augmentation, and adding multimodal data fusion processing modules. This will provide high-quality, multi-dimensional dataset support for AI agent training, thereby solidifying the technical foundation for AI agent applications.

(b) Upgrade UniBrain centered on AI agents (representing approximately 20% of the net proceeds from the Placing)

This portion of the proceeds will be used to focus on iterating the core capabilities of UniBrain, and, built upon the UniGPT large model, driving the evolution of AI agent technology from "single-scenario assistants" to "cross-scenario industry experts," while establishing data barriers and multimodal technology advantages in vertical domains.

In terms of R&D for vertical industries, based on the UniGPT Medical Large Model 5.0, we upgrade our solutions in the insurance field. The Company will develop targeted claims verification and risk control AI agents to achieve deep alignment among medical insurance policies, insurance contracts, and clinical data, thereby optimizing models for identifying abnormal claims. In the transportation sector, the Company will enhance the capabilities of multimodal customer service AI agents by integrating voice, image, and text interaction technologies, optimizing voice noise reduction algorithms and fuzzy intent recognition capabilities in noisy environments, and adapting to complex service scenarios at large transportation hubs such as airports and metro stations.

In terms of multilingual and dialect capability expansion, building upon the existing foundation of dozens of languages including Chinese, English, and Thai, the Company will add support for other Southeast Asian languages and domestic ethnic minority languages. Dialect support will cover most prefecture-level cities in China, reaching over 80% of dialect-speaking populations and regions.

In terms of on-device large model optimization, the Company will further develop model distillation technologies to adapt to IoT terminal devices with limited computing power. Meanwhile, the Company will build a rapid iteration platform for on-device models to support rapid customization and optimization according to the needs of different IoT scenarios (such as smart homes, smart cockpits, and elderly care devices), delivering cost-effective on-device AI solutions.

(c) Talent cultivation and joint R&D (representing approximately 6% of the net proceeds from the Placing)

This portion of the proceeds will be used to build an R&D talent ecosystem featuring "internal capability enhancement + external resource collaboration," providing human capital support for continuous technological innovation. In terms of internal talent training, the Company will comprehensively promote the in-depth application of AI R&D tools, covering the entire process of analysis, planning, design, and development, thereby enhancing the Company's overall R&D quality and efficiency. The Company will establish a tiered talent development system, providing algorithm fundamentals and platform operation training for junior R&D personnel, while setting up frontier technical development camps for senior engineers to encourage participation in internal technology research projects. Meanwhile, the Company will establish a technology sharing mechanism, regularly inviting internal technical experts and industry leaders to deliver lectures, facilitating knowledge accumulation and technological iteration.

In terms of external R&D collaboration, the Company will continue to deepen cooperation with top domestic universities to jointly train graduate students and postdoctoral researchers, thereby establishing a stable talent pipeline. At the same time, the Company will intensify overseas collaboration efforts, with a focus on expanding partnerships with universities in Hong Kong and Macau, conducting joint research on areas such as multilingual large models and AI agent collaboration technologies, and introducing international technological perspectives and high-caliber talent resources.

II. Invest in Emerging Business Opportunities

Approximately 40% of the net proceeds from the Placing will be allocated to invest in emerging business opportunities. The Company plans to expand its product development and sales teams in the following two areas and promote and market the Company's products through marketing activities (such as industry exhibitions) to build the Company's brand image and influence:

(a) Regional AI infrastructure and application platform

Focusing on regions with common regional attributes such as provinces, cities, or districts, and leveraging local AI industry strategic layouts and demand characteristics, the Company aims to build a comprehensive industrial service platform featuring "technology enablement + resource integration + operations-driven development." This platform comprises sub-platforms in three directions:

(1) Medical insurance and chronic disease management sub-platform. This is a regional (provincial, municipal, or district level) AI platform for medical insurance that unlocks the potential value of massive "dormant data" through centralized aggregation and intelligent analysis of region-wide medical data. The platform will rely on cutting-edge AI technologies such as large models to build a solid technological foundation, upon which diverse intelligent application modules will be developed. These modules will be deeply integrated with various business systems within the region, facilitating seamless data flow and achieving end-to-end integration of medical insurance services. More critically, the platform can precisely provide integrated services for medical insurance management and chronic disease prevention and control to regional residents, covering a wide range of scenarios including intelligent supervision of medical insurance expenses, precise auditing of personal medical insurance bills, post-diagnosis follow-up tracking for patients, dynamic registration of rehabilitation progress, and personalized treatment plan recommendations. This innovative model will deliver a groundbreaking healthcare experience for the general public in the region, particularly for chronic disease patients who rely on medical insurance services. It holds profound significance for improving the quality and efficiency of regional medical security services and solidifying the public health defense line. The Company has officially won the bid for the "Vertical Large Model Development and Scenario Application" project of the Jiangsu Provincial Medical Insurance Bureau. Development of this platform is currently underway, leveraging this project as a key opportunity.

(2) Regional characteristic industry service sub-platform. This sub-platform will focus on advantageous industries with specific regional characteristics. By conducting centralized collection and in-depth analysis of historical experience data accumulated during industrial development, it will efficiently unlock the core value of "dormant data." With cutting-edge AI technologies such as large models as the core support, the platform will establish a solid technological foundation, upon which diverse intelligent application carriers will be incubated. These will be deeply integrated with various application scenarios of downstream industries within the region, clearing the critical pathways for data-driven industrial development, thereby comprehensively enhancing industrial development efficiency and innovation capacity, and injecting strong intelligent momentum into the high-quality development of regional characteristic industries. The Company is currently in discussions with the government of Hui'an County, Quanzhou City, Fujian Province regarding the planning and development of the "Stone Carving Industry Modular Space and AI Agent Industrial Base" project.

(3) Comprehensive AI public service platform. Targeting the comprehensive industrial development needs of specific regions, this platform will conduct integrated collection, systematic analysis, and in-depth processing of both historical empirical data accumulated region-wide and real-time dynamic industrial data, and convert massive amounts of "dormant data" into high-value resources that drive industrial upgrading. With cutting-edge AI technologies such as large models as the core engine, the platform will establish a solid intelligent technological foundation, upon which diverse intelligent application carriers will be incubated. These will be deeply integrated with various application scenarios of downstream industries within the region, unblocking key nodes for the flow of data elements, thereby comprehensively enhancing industrial development efficiency and innovation levels, and injecting strong intelligent momentum into the high-quality development of regional comprehensive industries. The Company is currently in discussions with a certain municipal government to plan for the development of a "Municipal AI Public Service Platform" project.

(b) Industry AI agent products

With the emergence of various multimodal large models and specialized AI agents, digital employees and digital experts in professional fields are gradually becoming feasible in an increasing number of industries. The Company has established corresponding product reserves in this area and will further promote and expand industry penetration in the future.

The combination and application of large models and AI agents in various industries require the deep integration of industry demands, data, and the capabilities of large model AI agents to yield positive results. The Company plans to deeply collect, cleanse, and organize high-quality industry datasets in its current focus areas, such as healthcare, voice-enabled cockpits, public transportation, and smart marketing. Combined with its self-developed UniGPT foundation model, the Company will develop and enhance the performance of vertical large models for the above industries and build AI agent applications that solve practical problems in each industry. Specifically, the main tasks to be completed are as follows:

1. Based on high-quality industry data and combined with application scenarios in different industries, the Company will fine-tune and improve the UniGPT foundation model to build more precise and practical vertical large models;

2. The Company will further improve the Shouya AI agent platform and progressively enhance its workflow orchestration capabilities, providing support for the Company's in-house R&D team and external partners to develop AI agent applications for various industries;

3. The Company will conduct in-depth development of AI agent applications for the industries on which it currently focuses, including medical record generation, technical document review, anti-fraud, customer service quality inspection, and marketing data analysis, ensuring that AI agents provide high-quality, results-based services to industry clients in a transparent and controllable manner.

Through the aforementioned efforts, the Company will reconstruct applications in four key industries, including:

1. Smart healthcare: Leveraging large model technology, the Company will reconstruct applications such as medical record comprehension, medical record generation, chronic disease management, and medical insurance fund oversight. This will help reduce the workload of doctors in China and lower domestic medical insurance expenditures, thereby facilitating the Company's business development, such as the Jiangsu Provincial Hospital of Traditional Chinese Medicine project currently in progress.

2. Smart cockpit multimodal AI agent applications: Leveraging semantic large models and multimodal large models, the Company will redesign voice dialogue interfaces to significantly enhance support for dialects and minority languages, substantially improve the assistant's "intelligence," and provide a unified framework for integrating various vertical large model AI agent service applications, thereby delivering a natural, unified, and high-quality service experience to users. This will help the Company provide cost-effective solutions to new energy vehicle manufacturers in a highly competitive market, such as the Desay SV voice-enabled cockpit project currently in progress.

3. Smart transportation multimodal AI agent applications: This includes enhancing the scope and level of review for various forms of technical documents, evolving from the scenario of cross-document and cross-domain review of text only, to the scenario of cross-document and cross-domain review of multimodal materials such as text, graphics, and tables. This will help consolidate and preserve expertise from specialists across different domains into the Company's internal knowledge base, facilitating subsequent use and knowledge transfer, such as the group-level AI agent platform project for a certain urban rail transit company currently in progress.

4. Smart marketing: By fully utilizing the understanding and generation capabilities of multimodal large models, and through the transfer learning and rapid mastery of professional knowledge, such as acting as a "soft exoskeleton" to provide close assistance to sales personnel, the Company aims to enable the visualization, standardization, and professionalization of such person-to-person sales dialogue scenarios and empower clients across different industries to gain a competitive edge in fierce marketing competition, such as the CXMT smart marketing badge project currently in progress.

III. Working Capital and General Corporate Use

Approximately 10% of the net proceeds from the Placing will be allocated to talent recruitment and retention, working capital, and other administrative purposes to support the Company's business operations. This primarily includes: (a) rentals and property expenses of the Group; (b) renovation costs for newly established offices, showrooms, and other facilities; (c) personnel costs for administrative staff; and (d) other daily operating expenses.

OPINION OF THE BOARD

The Board is of the view that the 780,000 H Shares to be issued under the Placing represent approximately 1.84% of the issued H Shares and approximately 1.08% of the total issued shares of the Company as at the date of this announcement, respectively, which constitute a relatively small percentage and will not result in excessive dilution of the shareholding of existing shareholders. Furthermore, the Placing has clear intended uses of proceeds. Upon allocation of the relevant funds into the Company's R&D and business expansion, it will further improve the Company's technical strength and product competitiveness, enhance the Company's brand image and industry influence, drive the Company's rapid development in various vertical domains such as AI healthcare, transportation, and insurance, and create value for the Company and its shareholders, which is in the interests of the Company and its shareholders as a whole.

EFFECT OF THE PLACING ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

The table below sets forth the shareholding structure of the Company immediately prior to and after the completion of the Placing.

	Immediately prior to the completion of the Placing		Immediately after the completion of the Placing	
	Number of Shares	Approximate percentage of the total number of Shares in issue [Note 1]	Number of Shares	Approximate percentage of the total number of Shares in issue [Note 1]
Domestic unlisted Shares				
Core connected persons[Note 2]	16,658,441	23.40%	16,658,441	23.15%
Other holders of domestic unlisted Shares	8,336,620	11.71%	8,336,620	11.58%
Sub-total	**24,995,061**	**35.11%**	**24,995,061**	**34.73%**
Unlisted Foreign Shares				
Ming Fu Investments Limited[Note 3]	**4,570,649**	**6.42%**	**4,570,649**	**6.35%**
H Shares				
H Shares held by core connected persons[Note 4]	15,865,662	22.29%	15,865,662	22.05%
H Shares held by other public H Shareholders	25,756,221	36.18%	25,756,221	35.79%
H Shares held by Placees	—	—	780,000	1.08%
Sub-total	**41,621,883**	**58.47%**	**42,401,883**	**58.92%**
Total	**71,187,593**	**100.00%**	**71,967,593**	**100.00%**

Notes:

1. The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

2. This represents the sum of (i) 16,481,964 domestic unlisted Shares in which Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng, executive Directors of the Company, were deemed to be interested by virtue of their acting-in-concert arrangement. Dr. Liang Jia'en directly held 1,835,658 domestic unlisted Shares, and Dr. Kang Heng directly held 1,101,395 domestic unlisted Shares. Yunsi Shangyi directly held 11,697,500 domestic unlisted Shares, while Yunchuang Hudong directly held 1,847,411 domestic unlisted Shares. The general partner of each of Yunsi Shangyi and Yunchuang Hudong is Tianjin Yunsheng, which is held as to 99% of equity interests by Dr. Huang Wei and 1% of equity interests by Mr. Liu Shengping, the executive Director of the Company. Dr. Huang Wei is also the largest limited partner of Yunsi Shangyi with 82.59% partnership interest. Each of Yunsi Shangyi and Yunchuang Hudong is controlled by Dr. Huang Wei. As such, each of Tianjin Yunsheng and Dr. Huang Wei is deemed to be interested in the Shares held by Yunsi Shangyi and Yunchuang Hudong for the purpose of Part XV of the SFO; (ii) 176,477 domestic unlisted Shares of the Company in which Mr. Li Zhichao, non-executive Director of the Company, was deemed to be interested.

3. Ming Fu Investments Limited (a private joint stock company incorporated in Hong Kong) is directly held as to 96.94% by Qiming Venture Partners III, L.P., and the general partner of Qiming Venture Partners III, L.P. is Qiming GP III, L.P., and the general partner of which is Qiming Corporate GP III, Ltd., an exempted company incorporated in the Cayman Islands which is an Independent Third Party. As such, each of Qiming Venture Partners III, L.P., Qiming GP III, L.P. and Qiming Corporate GP III, Ltd. were deemed to be interested in the unlisted foreign Shares held by Ming Fu Investments Limited.

4. This represents the sum of (i) 7,063,697 H Shares in which Dr. Huang Wei, Dr. Liang Jia'en and Dr. Kang Heng, executive Directors of the Company, were deemed to be interested by virtue of their acting-in-concert arrangement. Dr. Liang Jia'en directly held 786,710 H Shares, and Dr. Kang Heng directly held 472,026 H Shares. Yunsi Shangyi directly held 5,013,214 H Shares, while Yunchuang Hudong directly held 791,747 H Share. The general partner of each of Yunsi Shangyi and Yunchuang Hudong is Tianjin Yunsheng, which is held as to 99% of equity interests by Dr. Huang Wei and 1% of equity interests by Mr. Liu Shengping, the executive Director of the Company. Dr. Huang Wei is also the largest limited partner of Yunsi Shangyi with 82.59% partnership interest. Each of Yunsi Shangyi and Yunchuang Hudong is controlled by Dr. Huang Wei. As such, each of Tianjin Yunsheng and Dr. Huang Wei is deemed to be interested in the Shares held by Yunsi Shangyi and Yunchuang Hudong for the purpose of Part XV of the SFO; (ii) 152,097 H Shares of the Company in which Mr. Li Zhichao, non-executive Director of the Company, was deemed to be interested; and (iii) 8,649,868 H Shares of the Company in which Li Shujun was deemed to be interested. TBP Sound Cloud Holdings (HK) Limited beneficially owned 6,202,020 H Shares, all of which were owned as to 100% by TBP Sound Cloud Holdings Limited. TBP Sound Cloud Holdings Limited is owned as to 100% by Trustbridge Partners V, L.P., while Trustbridge Partners V, L.P. is owned as to 100% by TB Partners GP5, L.P., which is owned as to 100% by TB Partners GP5 Limited. TBP Sound Cloud Holdings (HK) II Limited beneficially owned 2,447,848 H Shares, all of which were owned as to 100% by TBP Sound Cloud Holdings II Limited. TBP Sound Cloud Holdings II Limited is owned as to 100% by Trustbridge Partners VII, L.P., while Trustbridge Partners VII, L.P. is owned as to 100% by TB Partners GP7, L.P., which is owned as to 100% by TB Partners GP7 Limited. All of TB Partners GP5 Limited and TB Partners GP7 Limited were owned as to 100% by Li Shujun. As such, Li Shujun is deemed to be interested in 6,202,020 H Shares held by TBP Sound Cloud Holdings (HK) Limited and 2,447,848 H Shares held by TBP Sound Cloud Holdings (HK) II Limited for the purpose of Part XV of the SFO.

The Directors confirm that, immediately after the Completion of the Placing, the public float of the Company is no less than 25% of the Company's issued share capital as enlarged by the Placing.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

In accordance with the resolution in relation to the General Mandate passed at the extraordinary general meeting of the Company held on December 10, 2025, the general meeting of the Company has authorized the Board and the Board has further authorized the chairman of the Board and his authorized persons (unless otherwise provided by relevant laws and regulations in respect of matters of sub-delegation) to make corresponding amendments to the Articles of Association as it considers appropriate and necessary to reflect the registered capital and total number of the Shares of the Company as a result of issuance of additional Shares under the General Mandate.

As the completion of the Placing took place on January 22, 2026, the registered capital and total number of the Shares of the Company have been changed to RMB71,967,593 and 71,967,593 Shares, respectively. To reflect such changes in the registered capital and total number of the Shares of the Company, corresponding amendments to the Articles of Association (the "**Amendments to the Articles of Association**") have been made by the Company. The industrial and commercial registration, filing and other matters in respect of the Amendments to the Articles of Association will be completed with the relevant government or regulatory authorities in the PRC. The full text of the amended Articles of Association is available on the website of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the website of the Company (www.unisound.com).

By order of the Board
Unisound AI Technology Co., Ltd.
Dr. Huang Wei
Executive Director and General Manager

Beijing, the PRC
January 22, 2026

As of the date of this announcement, the board of directors of the Company comprises: (i) Dr. Liang Jia'en, Dr. Huang Wei, Dr. Kang Heng, Dr. Li Xiaohan and Dr. Liu Shengping as executive directors; (ii) Mr. Li Zhichao and Mr. Li Ang as non-executive directors; and (iii) Mr. Hu Jianjun, Dr. Fan Jian, Dr. Jin Huihua and Dr. Zhang Kun as independent non-executive directors.